Unknown

Dataset Information

0

Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.

ABSTRACT: A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker. Several of these dual inhibitors were highly potent (IC50 < 10 nM) and selective against PI3Kγ, δ and HDAC6 enzymes and exhibited good antiproliferative activity against multiple cancer cell lines. The lead compound 48c, induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients, while showing no cytotoxicity against normal PBMCs, NIH3T3, and HEK293 cells. Target engagement of PI3Kδ and HDAC6 by 48c was demonstrated in MV411 cells using the cellular thermal shift assay (CETSA). Compound 48c showed good pharmacokinetics properties in mice via intraperitoneal (ip) administration and provides a means to examine the biological effects of inhibiting these two important enzymes with a single molecule, either in vitro or in vivo.

SUBMITTER: Thakur A 

PROVIDER: S-EPMC7238858 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.

Thakur Ashish A   Tawa Gregory J GJ   Henderson Mark J MJ   Danchik Carina C   Liu Suiyang S   Shah Pranav P   Wang Amy Q AQ   Dunn Garrett G   Kabir Md M   Padilha Elias C EC   Xu Xin X   Simeonov Anton A   Kharbanda Surender S   Stone Richard R   Grewal Gurmit G  

Journal of medicinal chemistry 20200408 8

A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker. Several of these dual inhibitors were highly potent (IC<sub>50</sub> < 10 nM) and selective against PI3Kγ, δ and HDAC6 enzymes and exhibited good antiproliferative activity against multiple cancer cell lines. The lead compound <b>48c</b>, induced necrosis in several mutant  ...[more]

Similar Datasets

Unknown Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).
| S-EPMC7756583 | biostudies-literature
Unknown Molecular design, synthesis and <i>in vitro</i> biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer.
| S-EPMC8253220 | biostudies-literature
Unknown Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors.
| S-EPMC6651501 | biostudies-literature
Unknown Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.
| S-EPMC6466521 | biostudies-literature
Unknown Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
| S-EPMC4399029 | biostudies-literature
Unknown Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors.
| S-EPMC6099940 | biostudies-literature
Unknown Synthesis and HDAC inhibitory activity of pyrimidine-based hydroxamic acids
| S-EPMC9296983 | biostudies-literature
Unknown Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>: Design, Synthesis, and Antiproliferative Activity.
| S-EPMC10674657 | biostudies-literature
Unknown Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.
| S-EPMC10054477 | biostudies-literature
Unknown Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.
| S-EPMC10341573 | biostudies-literature